• SENSEX
    NIFTY 50
Healthcare

Biocon Biologics gets DCGI approval for use of CytoSorb in critical COVID-19 cases

Updated : May 27, 2020 09:03 AM IST

The license will be effective until COVID-19 is controlled in the country.
CytoSorb is aimed at reducing pro-inflammatory cytokines levels in critical COVID-19 patients who are being treated in ICU with confirmed or imminent respiratory failure.
Biocon Biologics gets DCGI approval for use of CytoSorb in critical COVID-19 cases

You May Also Like

Live TV
Advertisement